Physician profile
Gregory Alan Eippert
NPI 1730181934
$812,583.52
in general payments reported to CMS, 2019-2025
32 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $763 · 2021: $5,246 · 2022: $2,869 · 2023: $729K · 2024: $40K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $727K · Consulting Fee: $60K · Food and Beverage: $5,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $726,750.28 |
| Consulting Fee | $60,397.50 |
| Food and Beverage | $5,434.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $722,646.38 | 2023 | |
| Alcon Vision LLC | $79,455.15 | 2019-2025 | Clareon, Unity, Lensx |
| Microsurgical Technology, INC. | $5,591.25 | 2022-2025 | |
| Allergan, INC. | $808.79 | 2019-2022 | |
| Dutch Ophthalmic, USA | $663.69 | 2023-2025 | Eva, Combined Machine, Tissueblue |
| Novartis Pharmaceuticals Corporation | $461.43 | 2019-2023 | |
| Sight Sciences, INC. | $389.15 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ivantis, INC | $346.85 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $304.66 | 2019-2021 | |
| Shire North American Group INC | $226.79 | 2019 | |
| Abbvie INC. | $182.32 | 2022-2025 | |
| Oyster Point Pharma, INC. | $182.22 | 2022-2024 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $173.49 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $171.89 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| New World Medical,INC. | $135.09 | 2021-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $119.17 | 2021-2025 | |
| Aerie Pharmaceuticals, INC. | $97.58 | 2019-2021 | |
| Dompe US, INC. | $93.62 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $69.95 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Harrow Eye, LLC | $56.04 | 2024 | Vevye |
| Horizon Therapeutics Plc | $54.17 | 2022-2023 | Tepezza |
| Omeros Corporation | $49.98 | 2019 | |
| Glaukos Corporation | $44.74 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Thea Pharma INC. | $38.82 | 2024-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $36.45 | 2024 | Xdemvy |
| Amgen INC. | $31.40 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $26.06 | 2019-2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Astellas Pharma US INC | $17.49 | 2023 | Izervay |
| Mallinckrodt Hospital Products INC. | $13.32 | 2023 | Acthar |
| Ocular Therapeutix, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Eippert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.